JP2026021422A5 - - Google Patents

Info

Publication number
JP2026021422A5
JP2026021422A5 JP2025182180A JP2025182180A JP2026021422A5 JP 2026021422 A5 JP2026021422 A5 JP 2026021422A5 JP 2025182180 A JP2025182180 A JP 2025182180A JP 2025182180 A JP2025182180 A JP 2025182180A JP 2026021422 A5 JP2026021422 A5 JP 2026021422A5
Authority
JP
Japan
Prior art keywords
fluoro
composition according
oxoimidazole
dimethyloxan
methylindazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025182180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026021422A (ja
Filing date
Publication date
Priority claimed from PCT/US2023/021637 external-priority patent/WO2023220109A1/en
Application filed filed Critical
Publication of JP2026021422A publication Critical patent/JP2026021422A/ja
Publication of JP2026021422A5 publication Critical patent/JP2026021422A5/ja
Pending legal-status Critical Current

Links

JP2025182180A 2022-05-11 2025-10-29 Glp1医薬組成物 Pending JP2026021422A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340,591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions
JP2024566219A JP7767651B2 (ja) 2022-05-11 2023-05-10 Glp1医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2024566219A Division JP7767651B2 (ja) 2022-05-11 2023-05-10 Glp1医薬組成物

Publications (2)

Publication Number Publication Date
JP2026021422A JP2026021422A (ja) 2026-02-10
JP2026021422A5 true JP2026021422A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=86732348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024566219A Active JP7767651B2 (ja) 2022-05-11 2023-05-10 Glp1医薬組成物
JP2025182180A Pending JP2026021422A (ja) 2022-05-11 2025-10-29 Glp1医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024566219A Active JP7767651B2 (ja) 2022-05-11 2023-05-10 Glp1医薬組成物

Country Status (17)

Country Link
US (1) US20250302809A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522129A1 (cg-RX-API-DMAC7.html)
JP (2) JP7767651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250002778A (cg-RX-API-DMAC7.html)
CN (1) CN119173255A (cg-RX-API-DMAC7.html)
AR (1) AR129296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023269995A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253043A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003392A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015285A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000232A (cg-RX-API-DMAC7.html)
IL (1) IL316629A (cg-RX-API-DMAC7.html)
JO (1) JOP20240245A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013839A (cg-RX-API-DMAC7.html)
PE (2) PE20260136A1 (cg-RX-API-DMAC7.html)
TW (2) TW202508581A (cg-RX-API-DMAC7.html)
WO (1) WO2023220109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
KR20260118441A (ko) * 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
PL3984523T3 (pl) * 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ,インク. ソマトスタチン調節因子の製剤
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1

Similar Documents

Publication Publication Date Title
JP2025515706A5 (cg-RX-API-DMAC7.html)
IL316629A (en) GLP1 drug compounds
RU2574018C2 (ru) Легко дозируемый твердый препарат
CN103813807B (zh) 易服用性固体制剂
JP2010209104A5 (cg-RX-API-DMAC7.html)
JPH0399016A (ja) 二重被覆顆粒
JP5160423B2 (ja) 水易溶性薬物含有球状素顆粒の製造方法
IL316478A (en) GLP1 tablet preparations
KR20200010608A (ko) 서방성 토피라메이트 캡슐
NL8203343A (nl) Farmaceutisch preparaat.
CN102091051A (zh) 一种别嘌醇双释放制剂及其制备方法
JP2022553313A5 (cg-RX-API-DMAC7.html)
JP7676510B2 (ja) 口腔内崩壊錠
JP2018118966A5 (cg-RX-API-DMAC7.html)
AU640816B2 (en) Pharmaceutical compositions containing furan derivatives
JP2023536667A5 (cg-RX-API-DMAC7.html)
SA04250370A (ar) طرق وتكوينات لتثبيط السليكتين
JP2001522882A (ja) ザファルカストを含有する医薬品組成物
EP3973030A1 (en) Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing
JP2000026292A5 (cg-RX-API-DMAC7.html)
WO2001089573A1 (en) Method of stabilizing preparation
JP2019059702A (ja) 口腔内崩壊錠
JP2025535941A5 (cg-RX-API-DMAC7.html)
JP2024503689A5 (cg-RX-API-DMAC7.html)
RO132297A2 (ro) Compoziţie cu cefpodoxim proxetil cu eliberare extinsă